ID3 directly represses transactivation of the inhibitory receptor Sirpa by inhibiting binding of the E-box E2A and the MAP-kinase target ELK1 to the promoter/enhancer regions of the Sirpa gene, to a level low enough to allow KC activation by CD47-expressing cancer cells, at least in part through the activating receptor dectin-1. This evidence concerns the gene ID3 and cancer.